MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GREENBERG, D. A.
Right arrow Articles by SNYDER, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GREENBERG, D. A.
Right arrow Articles by SNYDER, S. H.

Molecular Pharmacology, Vol 14, 38-49, Copyright © 1978 by the American Society for Pharmacology and Experimental Therapeutics

Pharmacological Properties of [3H]Dihydroergokryptine Binding Sites Associated with Alpha Noradrenergic Receptors in Rat Brain Membranes

DAVID A. GREENBERG 1 and SOLOMON H. SNYDER 1

1 Departments of Pharmacology and Experimental Therapeutics and of Psychiatry and the Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

[3H]Dihydroergokryptine, a mixed agonist-antagonist at alpha noradrenergic receptors, binds in saturable fashion and with high affinity to membranes of rat cerebral cortex. Saturation studies reveal a dissociation constant (KD) of 1.6 nM and a receptor density of 21 pmoles/g, similar to the sum of the maximal number of binding sites observed for the [3H]alpha agonist clonidine and the [3H]alpha antagonist WB-4101 alone. The relative affinities of a wide range of drugs indicate that binding to cerebral cortical membranes selectively involves alpha noradrenergic receptors. Dopamine and serotonin inhibit binding only weakly, indicating that labeling of receptors for these neurotransmitters is negligible. The regional distribution of [3H]dihydroergokryptine binding in rat brain coincides with that observed for alpha receptor binding of [3H]clonidine and [3H]WB-4101, except for disproportionately high levels in corpus striatum. This suggests that in striatal membranes [3H]dihydroergokryptine is able to bind to dopamine as well as alpha receptors. The slopes of logit-log plots for the inhibition of [3H]dihydroergokryptine binding by mixed agonist-antagonists are about 1.0, while pure agonists or antagonists display shallower inhibition curves. These data are consistent with a model of the alpha noradrenergic receptor in which agonists and antagonists bind selectively to discrete, noninterconverting sites, while mixed agonist-antagonists can bind to either site.

Note:
ACKNOWLEDGMENTS We thank Dr. David C. U'Prichard and Stephen J. Peroutka for their helpful advice, and Mr. Gregory Mack for his skillful assistance. Drs. N. J. M. Birdsall and D. Rodbard provided helpful suggestions concerning analysis of data.

Submitted on March 28, 1977
Accepted on September 13, 1977







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1978 by the American Society for Pharmacology and Experimental Therapeutics